Alzheimer's Disease Clinical Trials

Showing 1801-1820 of 1,974 trials

Phase II Study for Amyloid Binding Imaging Study of [18F]AV-45 in Patients With Mild Cognitive Impairment, Alzheimer's Disease and Healthy Volunteers

NCT01238458

This study will recruit a total of 150 evaluable subjects (30 cognitively normal volunteers, and 60 MCI(Mild cognitive impairment), and 60 AD(Alzheimer's disease), respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping. Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events. This study is expected to be completed in a period of 3 years.

Alzheimer's Disease

Chang Gung Memorial Hospital150 participantsStarted Nov 2009

COMPLETEDPhase 3

Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline

NCT00506415

The purpose of this study was to support the optimal use of rivastigmine patch in long-term treatment of Alzheimer's Disease in patients demonstrating functional and cognitive decline at the target maintenance dose of rivastigmine patch 10 cm\^2.

Alzheimer Disease

Novartis Pharmaceuticals1,584 participantsStarted Jun 2007

Birmingham, Alabama, United States • Gilbert, Arizona, United States • Phoenix, Arizona, United States +142 more locations

Phase II Study for Amyloid Binding Imaging Study of [18F]AV-45 in Patients With Mild Cognitive Impairment, Alzheimer's Disease and Healthy Volunteers

Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline

Related Searches

Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease

Thalidomide for Patients With Mild to Moderate Alzheimer's Disease

Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals

Chronic Electrical Stimulation of Hypothalamus/Fornix in Alzheimer's Disease

A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers

Evaluation of Physician Training Methods to Read Florbetapir-PET Scans

A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease

Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease

Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia

Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain

A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease

Evaluation of Alteration by Magnetic Resonance Imaging (MRI) in Dementia Among Elderly Subjects

Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGAIT-II)

Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers

Memory Disorders Registry

Truncated and Extended Forms of Amyloid Beta Peptides in Alzheimer's Disease: Genesis, Toxicity and Identification as Biological Markers

A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease

Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients